Comment
doi: 10.1016/j.ijantimicag.2022.106575.
Epub 2022 Mar 20.
Viral Load Reduction and High-Dose Ivermectin in Early Treatment: A Reappraisal
Affiliations
- PMID: 35322790
- DOI: 10.1016/j.ijantimicag.2022.106575
Item in Clipboard
Comment
Viral Load Reduction and High-Dose Ivermectin in Early Treatment: A Reappraisal
Int J Antimicrob Agents.
2022 May.
No abstract available
Conflict of interest statement
Declaration of Competing Interest None.
Comment in
-
Reply to: Viral load reduction and high-dose ivermectin in early treatment: a reappraisal.Int J Antimicrob Agents. 2022 May;59(5):106576. doi: 10.1016/j.ijantimicag.2022.106576. Epub 2022 Mar 20. Int J Antimicrob Agents. 2022. PMID: 35322791 No abstract available.
Comment on
-
High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial.Int J Antimicrob Agents. 2022 Feb;59(2):106516. doi: 10.1016/j.ijantimicag.2021.106516. Epub 2022 Jan 6. Int J Antimicrob Agents. 2022. PMID: 34999239 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
